Complementary value of the Ki-67 proliferation index to the oncotype DX recurrence score

Katja Gwin, Marguerite Pinto, Fattaneh A. Tavassoli

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


Oncotype DX is a 21-gene assay that quantifies the recurrence risk in estrogen receptorg-positive breast cancer, which is expressed as the recurrence score (RS). Studies have shown that patients with a high-risk RS will most likely benefit from adjuvant chemotherapy, but there is no proven advantage for patients with a low-risk RS who still face an average recurrence risk of 7%. In this study, the relationship between the RS and the cell cycleg-related antigen Ki-67 was assessed in 32 breast carcinomas and evaluated for a potential association. Comparison of the RS with tumor type, grade, and the Ki-67 proliferation index (PI) revealed an overall concordance. However, some tumors with a low RS revealed a surprisingly high Ki-67 PI. These cases may correspond to the 7% of low-risk RS carcinomas that recur. Therefore, the authors propose a combined evaluation of the RS and Ki-67 PI to identify tumors with high recurrence potential from the low-risk and intermediate-risk RS groups.

Original languageEnglish (US)
Pages (from-to)303-310
Number of pages8
JournalInternational Journal of Surgical Pathology
Issue number4
StatePublished - Aug 2009


  • Breast
  • Carcinoma
  • Ki-67
  • Molecular profiling
  • Oncotype DX
  • Prognosis
  • Recurrence score

ASJC Scopus subject areas

  • Anatomy
  • Surgery
  • Pathology and Forensic Medicine


Dive into the research topics of 'Complementary value of the Ki-67 proliferation index to the oncotype DX recurrence score'. Together they form a unique fingerprint.

Cite this